Sugi Predict

Sugi Predict / Compounds / SCHEMBL19660965

SCHEMBL19660965

SCHEMBL19660965

CC(C)N(C(C)C)C(C)c1ccccc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ ADORA2A P29274 2/20 0.35
▸ FGR P09769 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ CSNK1A1 P48729 1/20 0.35
▸ CSNK1D P48730 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ HIPK2 Q9H2X6 1/20 0.35
▸ CSNK1G1 Q9HCP0 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473376 0.75 ALDH1A1 (0.39) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL3879880 0.75 CYP3A4 (0.43) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL5621598 0.75 CYP3A4 (0.43) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL19661042 0.74 GABRA1 (0.58) CYP3A4ALOX15SMN1; SMN2TDP1POLB
SCHEMBL6201553 0.74 CYP3A4 (0.48) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL21534246 0.74 CYP3A4 (0.47) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL104513 0.74 GABRA1 (0.50) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL1061130 0.74 CYP3A4 (0.48) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL16512108 0.74 CYP3A4 (0.48) CYP3A4ALOX15CASP1CASP7SMN1; SMN2
SCHEMBL732167 0.74 CYP3A4 (0.47) CYP3A4ALOX15CASP1CASP7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 — — US disclosed
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-08-15 — — US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 — — US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266549-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 CYP3A4 4260/4885ALOX15 3680/4885CASP1 2107/4885
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 CYP3A4 4414/4885ALOX15 3677/4885CASP1 2289/4885
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 CYP3A4 4414/4885ALOX15 3677/4885CASP1 2289/4885
US-10774092-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 CYP3A4 4260/4885ALOX15 3680/4885CASP1 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.